C1q类似蛋白4在乳腺癌中的表达及生存分析

Expression and Survival Analysis of C1q-Like Protein 4 in Breast Cancer

目的:探讨C1q类似蛋白4(C1ql4)在乳腺癌患者中的表达情况,分析C1ql4与乳腺癌临床病理特征和预后的关系。方法:通过免疫组化检测143例乳腺癌患者中C1ql4蛋白的表达情况,以20例乳腺纤维腺瘤组织作为对照。收集患者临床病理资料并随访生存预后情况,通过Kaplan-Meier生存曲线及多因素Cox回归分析C1ql4表达与预后的关系。以P<0.05表示差异具有统计学意义。结果:C1ql4蛋白阳性表达率在乳腺纤维腺瘤和乳腺癌中分别为15%(3/20)和98.6%(141/143)。在乳腺癌组织中C1ql4低表达占比47.6%(68/143),高表达占比51.0%(73/143)。C1ql4的表达与乳腺癌患者的肿瘤直径、淋巴结转移、TNM分期及分子分型有关(P<0.05)。C1ql4高表达组患者的预后更差(P<0.05)。多因素Cox回归分析显示TNM分期、分子分型以及C1ql4高表达是乳腺癌患者预后不良的独立危险因素(P<0.05)。结论:C1ql4在乳腺癌组织中高表达并且与预后不良病理参数相关。

Objective:To investigate the expression of C1ql4 in breast cancer patients,and to analyze the relationship between C1ql4 and relevant clinicopathological features and prognosis of breast cancer.Methods:The study examined the expression of C1ql4 protein using immunohistochemistry in 143 breast cancer patients,with 20 breast fibroadenoma tissues serving as controls.Clinical and pathological data were collected,and the survival and prognosis of patients were monitored.The association between C1ql4 expression and prognosis was analyzed using Kaplan-Meier survival curves and multivariate Cox regression.Differences were considered statistically significant at P<0.05.Results:The positive expression rate of C1ql4 protein was 15%(3/20)in breast fibroadenoma and 98.6%(141/143)in breast cancer.In breast cancer tissues,C1ql4 low expression was observed in 47.6%(68/143)of cases,while high expression was found in 51.0%(73/143)of cases.C1ql4 expression was associated with various clinical factors,including tumor diameter,lymph node metastasis,TNM stage,and molecular subtypes(P<0.05).Patients in the high expression group of C1ql4 had a worse prognosis(P<0.05).Multivariate Cox regression analysis demonstrated that TNM stage,molecular subtyping,and high C1ql4 expression were independent risk factors for an unfavorable prognosis in breast cancer patients(P<0.05).Conclusion:C1ql4 is highly expressed in breast cancer tissues and is associated with prognosis and adverse pathological parameters.